MARKET

EIKN

EIKN

Eikon Therapeutics
NASDAQ
9.97
+0.24
+2.47%
Opening 09:41 06/18 EDT
OPEN
9.80
PREV CLOSE
9.73
HIGH
10.20
LOW
9.80
VOLUME
11.87K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
7.90
MARKET CAP
539.76M
P/E (TTM)
-2.5323
1D
5D
1M
3M
1Y
5Y
1D
Eikon Therapeutics: Buy TLR Combinatory Potential Only After Lock-Up Expiry
Seeking Alpha · 1d ago
Eikon Therapeutics director Francisco Ma. Fatima files initial beneficial ownership statement
PUBT · 3d ago
Weekly Report: what happened at EIKN last week (0608-0612)?
Weekly Report · 3d ago
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
Seeking Alpha · 6d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 6d ago
Eikon Therapeutics Appoints Ma. Fatima Francisco to Board
TipRanks · 06/10 22:03
Eikon Therapeutics appoints Ma. Fatima D. Francisco to board
PUBT · 06/10 20:16
Eikon Therapeutics appoints P&G veteran Fatima Francisco to board
PUBT · 06/08 17:31
More
About EIKN
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.

Webull offers Eikon Therapeutics,Inc stock information, including NASDAQ: EIKN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIKN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIKN stock methods without spending real money on the virtual paper trading platform.